Product Description
AskGene Pharma using its SmartKine platform is developing ASKG322 which targets IL2 to treat solid tumors. (Sourced from: https://ask-gene.com/pipeline/)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AskGene
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|